GC
PSTV

Globeflex Capital’s Plus Therapeutics PSTV Stock Holding History

Globeflex Capital’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1
Closed -$894K – 557
2015
Q2 		$894K Buy
+1
New +$2.29M 0.16% 242

Other funds holding PSTV

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCMI
Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return

Globeflex Capital's PSTV Position: Q3 2015 in Review

Globeflex Capital sold out of Plus Therapeutics (PSTV) in Q3 2015, closing a stake of 1 share — an estimated $894K sold.

Globeflex Capital first reported a position in PSTV in Q2 2015 and held it in 1 quarter. The position peaked at $894K in Q2 2015. 3 funds tracked by Wall St. Rank hold PSTV as of Q3 2015.

  • Globeflex Capital reported no remaining Plus Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Globeflex Capital sold 1 Plus Therapeutics share in Q3 2015, an estimated $894K.
  • Globeflex Capital first reported a position in Plus Therapeutics in Q2 2015 and held it in 1 quarter.
  • Globeflex Capital's Plus Therapeutics position peaked at $894K in Q2 2015.
  • 3 funds tracked by Wall St. Rank held Plus Therapeutics as of Q3 2015.

Based on Globeflex Capital's 13F filing for Q3 2015, filed 9 Nov 2015.